2 news items
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
are recruited from clinical sites in the U.S. and Canada. The overall drop-out rate for both Phase 3 studies is in the range of 20% to 22%, which
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
SAVA
25 Mar 24
. Patients with mild-to-moderate Alzheimer's disease dementia who met study eligibility criteria were recruited into the Phase 3
- Prev
- 1
- Next